Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.
The in vitro activities of ABT-773, erythromycin, clarithromycin, and azithromycin were compared. ABT-773 was the most active compound against macrolide-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Enterococcus spp. and multidrug-resistant Streptococcus pneumoniae. It also had good activity against gram-negative and atypical respiratory tract pathogens and Helicobacter pylori.
Nilius
A M
AM
Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537, USA. angela.nilius@abbott.com
Bui
M H
MH
Almer
L
L
Hensey-Rudloff
D
D
Beyer
J
J
Ma
Z
Z
Or
Y S
YS
Flamm
R K
RK
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D016983:Enterococcus / Q000187:drug effects; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D048628:Ketolides; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013997:Time Factors
D000900:Anti-Bacterial Agents; D048628:Ketolides; D004917:Erythromycin; D017963:Azithromycin; D017291:Clarithromycin; C405499:cethromycin